Please login to the form below

Not currently logged in

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,

Latest news

More from news
Approximately 5 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...